More than half of all US adults are eligible for semaglutide therapy

Over 137 million US adults are eligible for semaglutide, driven by expanding indications for diabetes, weight management, and cardiovascular disease prevention.

US trade body again delays decision on Apple-Masimo patent dispute

Dive Brief: The U.S. International Trade Commission (ITC) has delayed a decision on a patent dispute between Apple and Masimo until October. A final vote

July 13, 2023

Innovative SRPFM technique enables ultra-sensitive force measurement at nanoscale in fluids

Groundbreaking research has revealed a new way to measure incredibly minute forces at the nanoscale in water, pushing the boundaries of what scientists know about

June 24, 2024

BioCryst Pharmaceuticals Inc Patent Filing for Complement System Inhibitors

Share this article According to GlobalData’s company profile on BioCryst Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. BioCryst Pharmaceuticals‘s grant

April 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.